GBR vs CCEL

For growth investors, Cryo-Cell International, Inc.

(CCEL) is the stronger pick with 2. 0% revenue growth year-over-year, versus -3. 9% for New Concept Energy, Inc. (GBR). Cryo-Cell International, Inc. (CCEL) offers the better valuation at 71. 6x trailing P/E, making it the more compelling value choice. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cryo-Cell International, Inc.

(CCEL) delivered a total return of -39. 6%, compared to -80. 4% for New Concept Energy, Inc. (GBR). Over 10 years, the gap is even starker: CCEL returned +57. 8% versus GBR's -57. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), New Concept Energy, Inc.

(GBR) is the lower-risk stock at -0. 15β versus Cryo-Cell International, Inc. 's 0. 35β — meaning CCEL is approximately -333% more volatile than GBR relative to the S&P 500.

By revenue growth (latest reported year), Cryo-Cell International, Inc.

(CCEL) is pulling ahead at 2. 0% versus -3. 9% for New Concept Energy, Inc. (GBR). Over a 3-year CAGR, GBR leads at 13. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cryo-Cell International, Inc.

(CCEL) is the more profitable company, earning 1. 3% net margin versus -12. 3% for New Concept Energy, Inc. — meaning it keeps 1. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10. 9% versus -162. 3% for GBR. At the gross margin level — before operating expenses — GBR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CCEL (6.

9% yield) pays a dividend. GBR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cryo-Cell International, Inc.

(CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), 6. 9% yield). Both have compounded well over 10 years (CCEL: +57. 8%, GBR: -57. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GBR (Real Estate) and CCEL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GBR is a small-cap quality compounder stock; CCEL is a small-cap income-oriented stock. CCEL pays a dividend while GBR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.